LEADER 00000cam a2200697 i 4500
001 on1162016614
003 OCoLC
005 20200821172250.1
006 m o d
007 cr |||||||||||
008 111222s2012 nyu ob 001 0 eng
010 2020678437
015 GBB237775|2bnb
016 7 016068635|2Uk
019 833181544
020 9781619426443|qebook
020 1619426447
020 |z1619426420|qpaperback
020 |z9781619426429|qpaperback
035 (OCoLC)1162016614|z(OCoLC)833181544
040 DLC|beng|erda|cDLC|dOCLCF|dVLY|dOCLCO|dN$T|dYDXCP|dE7B
|dEBLCP|dAGLDB|dVTS|dAU@|dSTF|dK6U
042 pcc
049 RIDW
050 00 RM373
072 7 MED|x071000|2bisacsh
082 04 615.37|223
090 RM373|b.R37 2012eb
245 00 Rapamycin :|beffectiveness, safety and drug interactions /
|cMartin J. Blanco and Agustina M. Torres, editors.
264 1 New York :|bNova Biomedical/Nova Science Publishers, Inc.,
|c[2012]
300 1 online resource.
336 text|btxt|2rdacontent
337 computer|bc|2rdamedia
338 online resource|bcr|2rdacarrier
347 text file|2rdaft
490 1 Pharmacology - research, safety testing and regulation
490 1 Organ transplantation rsearch horizons
504 Includes bibliographical references and index.
505 0 ""RAPAMYCIN""; ""EFFECTIVENESS, SAFETYAND DRUG
INTERACTIONS""; ""PHARMACOLOGY -- RESEARCH, SAFETYTESTING
AND REGULATION""; ""ORGAN TRANSPLANTATIONRESEARCH
HORIZONS""; ""Library of Congress Cataloging-in-
Publication Data""; ""Contents""; ""Preface""; ""mTOR
Inhibitors in Chronic LiverDiseases and Cancer"";
""Abstract""; ""1. Introduction""; ""2. mTOR Signaling in
the Liver""; ""mTOR Inhibitors""; ""3. mTOR Inhibition in
Chronic LiverDiseases""; ""Steatosis and Insulin
Resistance""; ""Steatohepatitis and Fibrogenesis"";
""Cirrhosis""
505 8 ""4. Relevance of mTOR Inhibition inHepatocellular
Carcinoma""""Conclusions""; ""References""; ""Starvation
Profileof mTOR Inhibitors""; ""Abstract""; ""I.
Introduction""; ""2. The Safety Profile of mTOR
Inhibitors""; ""2.1. Hyperglycemia""; ""2.2.
Dyslipidemia""; ""2.3. Asthenia""; ""2.4. Mucositis,
Stomatitis and Mouth Sores""; ""2.5. Pulmonary Toxicity"";
""2.6. Skin Toxicity""; ""2.7. Infection and Malignancy"";
""2.8. Bone Marrow Suppression""; ""2.9. Renal Function
Abnormalities""; ""3. mTOR Function in Normal
CellPhysiology""; ""3.1. Regulation of Growth Factor
Signaling""
505 8 ""3.2. Regulation of Cell Growth and Metabolism""""4. mTOR
Integrates Energy-SensingPathways""; ""4.1. AKT: The Link
betweenMetabolism and Extracellular Signals""; ""4.2. mTOR
Controls the Interfacebetween Nutrient Sensing and
Metabolism""; ""4.3. AMPK: A Low-Energy Checkpoint"";
""4.4. AMP-Activated Kinase Controls the Metabolic
Checkpoint""; ""5. mTOR Toxicity on Signaling Pathways"";
""6. Leptin""; ""7. Body Weight and Feeding""; ""8. Cross-
Talk among mTOR/PKA/AMP""; ""Conclusion""; ""References""
505 8 ""Identification of CandidateBiomarkers Predicting
Responseto Rapalogs Therapyin Human Cancer""""Abstract"";
""Introduction""; ""Pathway-based Identificationof
Predictive Biomarker""; ""Omics-based Identificationof
Predictive Biomarker""; ""Conclusion""; ""References"";
""Influence of Everolimus DrugRegime on Blood Cell
Subsetsin Kidney Transplant Patients""; ""Abstract"";
""Introduction""; ""Materials and Methods""; ""Blood
Leukocyte and LymphocyteSubset Measurement""; ""Results"";
""Discussion""; ""References""
505 8 ""The Emerging Mechanismof Limited Therapeutic Efficacyof
Rapamycin for Cancers""""Abstract""; ""Introduction"";
""a) Overview of Rapamycin""; ""b) Overview of the mTOR
Signaling Pathway""; ""c) Overview of Limited Clinical
Application of Rapamycinand Its Analogs for Cancer"";
""Rapamycin Can Only Partially InhibitmTORC1 Activity"";
""Rapamycin Cannot Inhibit mTORC2Activity upon Acute
Treatment""; ""PI3K/Akt Feedback Loop NegativelyRegulates
mTORC1 Activity""; ""Conclusions""; ""References"";
""Rapamycin Controls MultipleSignalling Pathways
Involvedin Cancer Cell Survival*""; ""Abstract""
546 English.
588 Description based on print version record.
590 eBooks on EBSCOhost|bEBSCO eBook Subscription Academic
Collection - North America
650 0 Rapamycin.|0https://id.loc.gov/authorities/subjects/
sh2001005861
650 7 Rapamycin.|2fast|0https://id.worldcat.org/fast/1089963
655 0 Electronic books.
655 4 Electronic books.
700 1 Blanco, Martin J.,|0https://id.loc.gov/authorities/names/
nb2013005116|eeditor.
700 1 Torres, Agustina M.,|0https://id.loc.gov/authorities/names
/nb2013005117|eeditor.
776 08 |iPrint version:|tRapamycin|dNew York : Nova Science
Publishers, c2012.|z9781619426429 (pbk.)|w(DLC)
2011946012
830 0 Pharmacology-research, safety testing, and regulation
series.|0https://id.loc.gov/authorities/names/n2010180130
856 40 |uhttps://rider.idm.oclc.org/login?url=http://
search.ebscohost.com/login.aspx?direct=true&scope=site&
db=nlebk&AN=541043|zOnline ebook via EBSCO. Access
restricted to current Rider University students, faculty,
and staff.
856 42 |3Instructions for reading/downloading the EBSCO version
of this ebook|uhttp://guides.rider.edu/ebooks/ebsco
901 MARCIVE 20231220
948 |d20201113|cEBSCO|tEBSCOebooksacademic MERGE AUG-DEC2020
577 |lridw
948 |d20160607|cEBSCO|tebscoebooksacademic|lridw
994 92|bRID
